Member

Shear Kershman Labs, Inc


Advanced Drug Delivery & Formulation Partner for Medical Countermeasures, Biologics and Pharmaceutical Innovation Shear Kershman Labs (SKL) is an innovation-driven pharmaceutical development company specializing in advanced drug delivery, formulation science, and translational product development. Our proprietary BioViscid™ platform enables prolonged mucosal residence, improved drug absorption, protection of sensitive biologics, and reformulation of existing therapeutics into more effective patient-friendly dosage forms. For more than four decades, SKL has helped pharmaceutical, biotechnology, government, and consumer healthcare organizations solve difficult formulation challenges—from early feasibility through manufacturing strategy.

Industries

Biologics & Pharmaceutical Formulations
Medical Countermeasures
Hormones & Peptides
Wound Healing
Veterinary Medicine

Nr. of Employees

small (1-50)

Shear Kershman Labs, Inc

701 Crown Industrial Court Suite F Chesterfield, MO 63005


Products

BioViscid Mucosal Drug Delivery Platform

BioViscid™ is SKL’s proprietary mucoadhesive drug-delivery platform designed to improve the delivery of small molecules, biologics and peptides across mucosal surfaces. The platform supports buccal, sublingual, oral transmucosal, nasal, topical and other mucosal applications and may enable improved absorption, prolonged residence time, controlled release and reduced dependence on injectable administration. BioViscid can be applied to existing or novel therapeutic actives through collaborative formulation and development programs. Current development areas include peptides and biologics, hormones, medical countermeasures, oral and dental therapeutics, wound healing and veterinary medicine.


Services

SKL partners with pharmaceutical, biotechnology, government and animal-health organizations to formulate and optimize therapeutic actives using proprietary and conventional drug-delivery technologies. Capabilities include feasibility assessment, formulation development, mucosal and topical delivery, controlled release, stability optimization, prototype development, analytical support, manufacturing scale-up and IND-enabling formulation support.

Mucosal Delivery & Bioavailability Enhancement

Development of buccal, sublingual, oral transmucosal, nasal and other mucosal formulations designed to improve drug residence time, absorption and therapeutic performance.

Government & Defense Medical Product Development

Formulation and drug-delivery development supporting medical countermeasures, biologics, peptides and other therapeutics relevant to DoD and federal health priorities, including opportunities to improve stability, administration and field usability.

Expertise Areas

  • Sustained release and controlled drug delivery
  • Pharmaceutical formulation development
  • Transdermal and topical product development
  • Injectable pharmaceuticals and device integration
  • Show More (5)

Key Technologies

  • Controlled release drug delivery systems
  • Encapsulation technologies
  • Pilot-scale mixed modality processing
  • Stability chambers
  • Show More (4)

Key People

Doreen Linze

VP R&D

LinkedIn

Frank Maresca

Partner

LinkedIn

Dr Blake Hawley

Partner

LinkedIn

Dr Steven Brooks

Chief Medical Officer

LinkedIn

News & Updates

Recognized for the development and patenting of a method to make methamphetamine-resistant cold medicine containing pseudoephedrine.

Product developed provided new generic treatment options for cystic fibrosis patients.

Recognized for pioneering the first commercially-available sustained release technology for pharmaceuticals.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.